NewEdge Advisors LLC Raises Stock Position in Stryker Corporation $SYK

NewEdge Advisors LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 6.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,049 shares of the medical technology company’s stock after purchasing an additional 1,848 shares during the period. NewEdge Advisors LLC’s holdings in Stryker were worth $9,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Varma Mutual Pension Insurance Co raised its position in Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares in the last quarter. QRG Capital Management Inc. boosted its position in Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after purchasing an additional 4,186 shares in the last quarter. Swedbank AB boosted its position in Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after purchasing an additional 6,367 shares during the period. Finally, Rathbones Group PLC increased its holdings in shares of Stryker by 647.9% during the 4th quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock valued at $77,065,000 after purchasing an additional 189,948 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $338.85 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a fifty day moving average of $320.11 and a 200 day moving average of $333.92. The firm has a market cap of $129.97 billion, a PE ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. The company’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SYK. Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Citigroup reissued an “outperform” rating on shares of Stryker in a research note on Monday, August 3rd. Argus set a $370.00 target price on Stryker in a research report on Thursday, July 9th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.